The clinical application of psychedelics like MDMA, psilocybin, and LSD is gaining support daily. The class of drugs is quickly shedding its stigma as more research demonstrates the promise of treating ever-pervasive mental health disorders like depression, anxiety, and bipolar. Even with a growing acceptance, psychedelic therapies face significant challenges before they have a chance at making it to the market. 

At BIO International Convention in San Diego, five esteemed professionals in the field discussed the hurdles clinical psychedelic development faces before it can benefit the millions of people in need of better mental health treatments. The panel highlighted problems like scalability, clinical limitations, intellectual property issues, and overcoming the stigma of psychedelics.